CSIMarket
 
Zomedica Corp   (ZOM)
 

Robust 46.148% Top-line rise at ZOM in the January to March 31 2023 time-frame

ZOM delivered first quarter of 2023 operating shortfall of $-7.512 million


Published 2023-05-14T04:11:53+00:00
Goran Soko / CSIMarket.com Contributer


Dryvax_pdThe Major Pharmaceutical Preparations company increased a shortfall per share at $-0.01 per share in the January to March 31 2023 time-frame, although its revenue surged by 46.148 % to $5.48 million from the corresponding quarter a year before.

In the previous quarter the company realized Revenue of $6.16 million and $0.00 per share.


For the first quarter of 2023 earnings season Zomedica Corp realized net shortfall of $-6.385 million, higher than $-3.937 million a year ago.


Zomedica Corp is expected to report next financial recent numbers on August 14, 2023.



Zomedica's Dividend Comparisons

Zomedica's Receivables Turnover Ratio





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071